Search Results - "Chalayer, E"

Sarcoidosis and lymphoma: a comparative study by Chalayer, É, Bachy, E, Occelli, P, Weiler, L, Faurie, P, Ghesquieres, H, Pavic, M, Broussolle, C, Sève, P

“…To assess the clinical features and outcome of lymphoma when associated with sarcoidosis and to determine whether this association gives lymphoma a better…”
Get full text

Platelet transfusion in adults: An update by Garraud, O., Hamzeh-Cognasse, H., Chalayer, E., Duchez, A.C., Tardy, B., Oriol, P., Haddad, A., Guyotat, D., Cognasse, F.

“…Many patients worldwide receive platelet components (PCs) through the transfusion of diverse types of blood components. PC transfusions are essential for the…”
Get full text

Bone marrow involvement in systemic lupus erythematosus by Chalayer, E, Costedoat-Chalumeau, N, Beyne-Rauzy, O, Ninet, J, Durupt, S, Tebib, J, Asli, B, Lambotte, O, Ffrench, M, Vasselon, C, Cathébras, P

“…Besides peripheral cytopenias, bone marrow abnormalities, such as fibrosis, pure red cell aplasia and aplastic anemia have been reported in patients with…”
Get full text

Myelofibrosis: A review by Genthon, A, Killian, M, Mertz, P, Cathebras, P, Gimenez De Mestral, S, Guyotat, D, Chalayer, E

“…Myelofibrosis is a BCR-ABL1-negative chronic myeloproliferative neoplasm that includes primary myelofibrosis, post-polycythemia vera myelofibrosis, and…”
Get full text

Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? by Chalayer, E, Chapelle, C, Leleu, X, Elalamy, I, Laporte, S, Tardy, B

Get full text

The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials: comment by Tardy, B., Chalayer, E., Chapelle, C., Mismetti, P.

Get full text

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK by Roussel, M., Pirotte, M., Gounot, R., Queru, K., Rizzo, O., Royer, B., Harel, S., Desport, E., Huart, A., Niault, M., Karlin, L., Decaux, O., Chalopin, T., Carpentier, B., Macro, M., Vignon, M., Chalayer, E., Stoppa, AM, Bridoux, F., Jaccard, A.

Get full text

A Hospice and Palliative Care Bed Dedicated to Patients Admitted to the Emergency Department for End-of-Life Care by Lafond, Pierre, Chalayer, E., Roussier, M., Weber, E., Lacoin-Reynaud, Q., Tardy, B.

“…A hospice and palliative care (PC) bed was created in 2006, located within a quiet area of our intensive care unit, in order to admit terminally ill patients…”
Get full text

Carcinomatosis lymphangitis and pleurisy after allo-SCT in two patients with secondary leukemia after breast cancer by Chalayer, E, Tavernier-Tardy, E, Clavreul, G, Bay, J-O, Cornillon, J

Get full text

Newly diagnosed multiple myeloma: Do we need to propose thromboprophylaxis? by Chalayer, E, Augeul-Meunier, K, Tardy-Poncet, B, Cathebras, P, Guyotat, D, Tardy, B

“…The incidence of venous thromboembolism in multiple myeloma depends on the disease characteristics that include recent diagnosis, persistent or recurrent…”
Get full text

Myélome multiple de novo : faut-il proposer une prophylaxie antithrombotique ? by Chalayer, E., Augeul-Meunier, K., Tardy-Poncet, B., Cathebras, P., Guyotat, D., Tardy, B.

“…L’incidence de la maladie veineuse thromboembolique (MVTE) au cours du myélome multiple (MM) dépend de son caractère de novo, persistant ou récidivant, des…”
Get full text

PO-05: D-dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma by Charles, S., Chaudier, A., Fatrara, T., Daguenet, E., Karlin, L., Montmartin, A., Boussoualim, K., Tardy-Poncet, B., Tardy, B., Lecompte, T., Guyotat, D., Chalayer, E.

Get full text

PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose? by Teste, A., Thollot, H., Tinquaut, F., Sotton, S., Tardy, B., Moreau, P., Fermand, J.P., Hulin, C., Elalamy, I., Leleu, X., Guyotat, D., Chalayer, E.

Get full text

Lymphomes T périphériques : manifestations cliniques atypiques et stratégies diagnostiques by Dutour, M., Fouillet, L., Chalayer, E., Cathébras, P.

“…Les lymphomes T périphériques sont des hémopathies lymphoïdes issues d’une prolifération clonale de lymphocytes T ou Natural Killer matures non primitivement…”
Get full text

TEMPORARY REMOVAL: PO-05: D-dimers cut off level to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma by Charles, S, Chaudier, A, Fatrara, T, Daguenet, E, Karlin, L, Montmartin, A, Boussoualim, K, Tardy-Poncet, B, Tardy, B, Lecompte, T, Guyotat, D, Chalayer, E

“…The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the…”
Get full text

Découverte concomitante d’une maladie de Takayasu et d’une maladie de Hodgkin by Antoine, P., Carneiro-Esteves, L., Chalayer, E., Cathébras, P.

“…Nous rapportons le cas d’une patiente chez qui ont été découverts de manière concomitante et presque fortuite une maladie de Takayasu et un lymphome de…”
Get full text

Sarcoïdose et lymphome : étude multicentrique, à propos de 46 cas by Charriere, R., El Jammal, T., Chalayer, E., Ghesquieres, H., Bert, A., Michallet, A.S., Yvan, J., Gerfaud-Valentin, M., Sève, P.

Get full text

Les myélofibroses by Genthon, A., Killian, M., Mertz, P., Cathebras, P., Gimenez De Mestral, S., Guyotat, D., Chalayer, E.

“…La myélofibrose est un syndrome myéloprolifératif chronique BCR-ABL1 négatif. On distingue la myélofibrose primitive, et la myélofibrose secondaire à une…”
Get full text

Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study by Chalayer, Emilie, Tardy‐Poncet, Brigitte, Karlin, Lionel, Chapelle, Céline, Montmartin, Aurélie, Piot, Michèle, Guyotat, Denis, Collet, Philippe, Lecompte, Thomas, Tardy, Bernard

“…Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly during the first months of treatment including immunomodulatory drugs (IMiDs)…”
Get full text

Myelofibrosis: A review by Genthon, A, Killian, M, Mertz, P, Cathebras, P, Gimenez De Mestral, S, Guyotat, D, Chalayer, E

Get full text